Revive Therapeutics Ltd. (RVVTF)
- GlobeNewswire
PharmAla Named Exclusive MDMA Supplier to Revive Therapeutics
PharmAla Biotech will provide MDMA to Revive Therapeutics in their development of an MDMA Microneedle PatchVANCOUVER, British Columbia, Feb. 06, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla”)(CSE: MDMA) is pleased to announce that it has signed on to act as exclusive supplier of both GMP LaNeo MDMA and Engineering MDMA to Revive Therapeutics (CSE:RVV) (OTCQB: RVVTF). On Friday, February 3, Revive Therapeutics announced a licensing agreement with Pharmather Holdings to licen
- GlobeNewswire
Revive Therapeutics Secures MDMA Supply from PharmAla Biotech for MDMA Transdermal Patch Development
TORONTO, Feb. 06, 2023 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce it has entered into a supply agreement with PharmAla Biotech Holdings Inc. (“PharmAla”) (CSE: MDMA) to obtain PharmAla’s LaNeo, GMP source of 3,4-Methylenedioxymethamphetamine (“MDMA”), for the development of
- GlobeNewswire
Revive Therapeutics Enters into Research Collaboration Agreement with PharmaTher for Development of MDMA Transdermal Patch
TORONTO, Feb. 03, 2023 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce it has entered into a research collaboration agreement with PharmaTher Holdings Ltd. (“PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM) to evaluate the delivery of 3,4-Methylenedioxymethamphetamine (“MDMA”) using Pharm
